Advancements in the development of non-BET bromodomain chemical probes by Clegg, Michael A. et al.
  
1 
 
Advancements in the 
Development of non-BET 
Bromodomain Chemical Probes 
Michael A. Clegg[a],[b], Nicholas C. O. 
Tomkinson[b], Rab K. Prinjha[a] and Philip G. 
Humphreys*[a]  
 
1 
    
≥10 
No. of Inhibitors No. of Chemotypes 
1 ≥7     
  
2 
 
Abstract: The bromodomain and extra terminal (BET) family of 
bromodomain containing proteins (BCPs) have been the subject 
of extensive research over the past decade, resulting in a plethora 
of high quality chemical probes for their tandem bromodomains. 
In turn, these chemical probes have helped reveal the profound 
biological role of the BET bromodomains and their role in disease, 
ultimately leading to a number of molecules in active clinical 
development. However, the BET subfamily represents just 8/61 of 
the known human bromodomains, and attention has now 
expanded to the biological role of the remaining 53 non-BET 
bromodomains. Rapid growth of this research area has been 
accompanied by a greater understanding of the requirements for 
an effective chemical probe and has led to a number of new non-
BET bromodomain chemical probes being developed. Recent 
efforts since December 2015 will be discussed here, highlighting 
the particular strengths/caveats of each molecule, and the value 
they add in validating an untapped source of therapeutics. 
1. Introduction 
Epigenetics is defined as the study of heritable changes in gene 
expression without alteration of the underlying DNA sequence.1 
Instead, epigenetic modifications operate by disrupting the 
structure of chromatin and thus modulating the accessibility of 
DNA. One of the most extensively studied and well recognised 
modifications is the acetylation of lysine residues present on 
histone tails,2–4 a process regulated by histone acetyltransferases 
(HATs) and histone deacetyltransferases (HDACs), which ‘write’ 
and ‘erase’ acetyl marks respectively. 
Acetylated lysine (KAc) residues are recognised by ‘reader’ 
modules known as bromodomains which selectively bind to 
context sensitive acetylated lysine residues, recruiting cellular 
transcriptional machinery to a specific histone mark, and 
regulating gene expression. The structure of bromodomains is 
comprised of a unique left-handed bundle consisting of four 
antiparallel alpha helices (αZ, αA, αB, and αC) connected by two 
flexible loop regions (ZA and BC), which together form the 
hydrophobic pocket for acetylated lysine binding (Figure 1).5 
Within the binding pocket of typical human bromodomains (48/61) 
are two conserved amino acid residues (Asn and Tyr) which 
together form the two key interactions for acetylated lysine 
recognition. More specifically, a direct hydrogen bond is formed 
between the KAc carbonyl moiety and the NH2 of the conserved 
Asn residue, whilst a water mediated hydrogen bond interaction 
is formed to the hydroxy group of the conserved Tyr. The size of 
the KAc binding pocket and the conserved H-bonding interactions 
has led to substantial success in the development of small 
molecule typical bromodomain inhibitors, designed to 
competitively mimic these interactions. By contrast, in 13/61 of 
human bromodomains, the conserved Asn residue is mutated to 
either a Tyr, Thr or Asp. These are known as ‘atypical’ 
bromodomains and have proven more difficult to design 
competitive inhibitors for in the past. 
Despite a good understanding of bromodomain function and 
structure, the biological role of BCPs in modulating healthy and 
disease states is still unclear. As a result, there is a need for high 
quality chemical probes to be used as part of pre-clinical target 
validation to help elucidate the biological functions of these 
proteins, and specifically, whether the bromodomain regions 
themselves play an active role. 
A chemical probe is a tool molecule that selectively binds to 
a target and is used to elucidate its biological function,6,7 helping 
bridge together chemical biology and drug discovery. In contrast 
to other target validation methods, such as gene knockdown, in 
which the actions of the entire complex is blocked, chemical 
probes allow for elucidation of the biological roles of each 
individual domain, making them particularly attractive for 
bromodomain target validation. 
 
Figure 1. X-ray crystal structure of BRD4(1), highlighting the four antiparallel 
alpha helices, loop regions, and the key interactions formed between typical 
bromodomains and acetylated lysines. 
The necessity for high quality probes has been highlighted 
in a number of excellent reviews8–10, with clear guidelines defined 
for probe generation. This, combined with bodies such as the 
SGC, Chemical Probes Portal and the Open Science Probe 
Project, aimed at increasing the quality, availability and 
reproducibility of research using chemical probes, has led to an 
important and necessary improvement to the quality and 
supporting data accompanying molecules being proposed as 
chemical probes. To summarise Bunnage and co-workers11, for 
effective target validation a chemical probe must: 1) be able to 
reach the site of action at pharmacologically relevant 
concentrations; 2) display in vitro evidence of target engagement  
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and selectivity; 3) provide sufficient data to assign phenotypic 
results to an original structure or a well characterized derivative; 
and 4) provide cellular activity data to answer a hypothesis on the 
role of the target. Consequently, the following criteria are used 
within GSK as guidelines when designing bromodomain chemical 
probes to ensure all 4 of these objectives can be fulfilled.  
1. pIC50 ≥7 (IC50 <100 nM) against target in a biochemical 
assay. 
2. > ×100 selective against BET bromodomains (for which a 
strong biological phenotype is known). 
3. > ×30 selective against other non-BET bromodomains.  
4. Understanding of broader off-target activity. 
5. Suitable solubility and permeability to ensure exposure at 
target site. 
6. Cellular activity at <1 µM concentrations (pIC50 > 6). 
7. Be accompanied by a structurally related negative control. 
8. Expand the structural diversity of bromodomain chemical 
probes. 
Pivotal to the applicability of a chemical probe is the allocation of 
an observed phenotype to target inhibition. Therefore, when 
developing small molecule bromodomain inhibitors, selectivity is 
heavily scrutinized, in particular against the BET bromodomain 
family for which a strong biological phenotype is known. From 
GSK’s own experience, a 100-fold selectivity window is required 
for adequate biological interpretation. Additionally, small molecule 
inhibitors will inherently hit a multitude of biological targets. 
Moving forward, the advent of chemoproteomic profiling allows for 
more holistic compound profiling,12 however until then, any 
additional information regarding off-target affinity that can be 
obtained, typically via screening against internal panels available 
to the institute or via a CEREP panel, is desired. 
In the absence of infinite off-target screening, the presence 
of equally well characterized structurally related negative control 
compounds, and additional inhibitors of different chemotypes help 
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mitigate this issue, providing further bias to suggest an observed 
phenotype is due to target inhibition.  
The advanced understanding of BET bromodomain 
pharmacology and the small molecules progressing through 
clinical trials, is in part due to the ready availability of high quality 
chemical probes for these targets. With BCP dysregulation 
implicated in a number of disease states, there has been a surge 
of interest in non-BET bromodomain chemical probes to aid target 
validation of these epigenetic reader modules. This area was 
reviewed previously in 2015 by 3 of the corresponding authors.13 
Since this review, however, the field has progressed rapidly with 
a number of new chemical probes being developed and disclosed 
(Figure 2). The quality of non-BET bromodomain chemical 
probes, and the variety of chemotypes included, has also 
advanced dramatically, reflecting the awareness and uptake of 
the guidelines mentioned previously. The generation of high 
quality chemical probes, and the structural information typically 
obtained during their development, has also facilitated the 
development of more sophisticated bifunctional chemical biology 
tools. These include bivalent inhibitors, proteolysis targeting 
chimeras (PROTACs) and photoaffinity probes which can provide 
additional information into the validation of biological targets.14 
All non-BET bromodomain tool molecules disclosed 
between December 2015 and October 2018 shall be reviewed 
here with close attention to the aforementioned criteria, noting any 
opportunities for future probe development and their applicability 
as chemical probes for target validation. For reader clarity, all 
bromodomain inhibitors have been drawn (where possible) with 
the acetylated lysine mimetic in the top-left/bottom-left corner and, 
when available, a crystal structure of the inhibitor bound to the 
target protein has been included. 
 
Figure 2. Bromodomain phylogenetic tree highlighting the number of different inhibitors (size of spot) for a given bromodomain and the number of unique chemotypes 
(colour of spot) presented by these inhibitors. BET subfamily has been greyed out for clarity.
  
5 
 
2. Typical Non-BET Bromodomain Inhibitors 
CECR2 
As the name suggests, cat eye syndrome chromosome region 
candidate 2 (CECR2) has an active role in human disorder cat 
eye syndrome, which in turn is attributable to eye, heart, kidney, 
face and skeletal malformations. CECR2 is predominantly 
expressed in the nervous system, with CECR2 deletion being 
associated with neural tube defects. CECR2 has also been shown 
to inhibit γ-H2AX following DNA double strand breaks, and 
consequently is thought to play a role in DNA damage response.15  
 At the end of our previous review, CECR2 had no reported 
chemical probes, with only mildly potent (pIC50 = 5.8-6.6) pan 
inhibitors available at that time. Since then, the first CECR2 
chemical probes have been developed and disclosed. 
Collaborative work between Novartis and the SGC has led 
to the development of NVS-CECR2-1 (1), a potent and selective 
CECR2 bromodomain inhibitor. 1’s potency for CECR2 was 
demonstrated using an Alpha screen assay (pIC50 = 7.3), and was 
reported to be inactive against a bromodomain panel of 48 targets, 
highlighting its desired selectivity, although no data is provided.16 
Furthermore, 1 reports good selectivity against pharmacologically 
relevant off targets where tested, showing no activity in kinase, 
protease and receptor panels, although again no data is provided. 
Additionally, 1 is accompanied by a structurally similar negative 
control in the form of NVS-CECR2-C which is inactive against 
CECR2, although no structure is reported. The permeability of 1 
is not provided, but fluorescence recovery after photobleaching 
(FRAP) data indicates cell penetration and cellular activity at 0.1 
µM. Finally, poor solubility is mentioned but no data provided. 
Bromodomain selectivity, in particular over the BET subfamily. Is 
not specified, potentially limiting the application of 1 as a chemical 
probe for CECR2, however this likely will be addressed when the 
work is published. 
 Crawford and co-workers. have also disclosed a potent and 
selective inhibitor of CECR2, known as GNE-886 (3). An initial 
screen of 600 compounds led to the N-methyl pyrrolopyridinone 
hit compound 2 which was prioritised due to its selectivity over the 
BET bromodomains (BRD4 pIC50 <4.7), and minor selectivity over 
BRD9 (×2), despite showing a greater potency towards TAF1 than 
CECR2. Structure based lead optimization was used to improve 
the selectivity over BRD9 and TAF1, resulting in 3, which 
displayed potency for CECR2 (pIC50 = 7.8). 3 also demonstrated 
>1000-fold selectivity over BET bromodomains (pIC50 <4.7), 100-
fold selectivity over BRD9 (pIC50 = 5.8), and 80-fold selectivity 
over TAF1 (pIC50 = 5.9) which were all measured within a TR-
FRET assay. Similarly, 3 appeared selective against a panel of 
35 diverse kinases, with no kinase inhibited >20% at 1 µM. 
Moreover, 3 is soluble (609 µg/mL) and the displacement of 
CECR2-Zs Green fusion protein from chromatin was measured 
(pEC50 = 6.4), demonstrating permeability and cellular activity. 
Unfortunately, 3 does not have a known structurally related 
negative control.17  
 Finally, collaborative work between Takeda and the SGC 
has led to the discovery of TP-238 (4), a reported dual chemical 
probe for CECR2 and BPTF.18 4 displayed potency for both 
CECR2 (pIC50 = 7.5) and BPTF (pIC50 = 6.5) in an Alpha screen  
 
 
Figure 3. a) Structure of CECR2 chemical probe 1; b) Structure of CECR2 
chemical probe 3 and initial hit compound 2; c) Structure of CECR2/BPTF 
inhibitor 4 and accompanying negative control 5. 
 
assay and, whilst no solubility or permeability data is provided, 
cellular activity was demonstrated at submicromolar 
concentrations in a NanoBRET assay for both CECR2 and BPTF. 
Micromolar potency against BRD9 (pIC50 = 5.9) is reported as the 
closest off-target bromodomain inhibition although no further data 
is provided. Additionally, no activity at 1 µM was observed against 
a panel of 338 kinases, providing insight into 4’s potential off-
target activity. TP-422 (5), an accompanying negative control was 
also disclosed and is reported to be completely inactive against 
CECR2 and BPTF, although no mention of concentration is 
provided. Hopefully further data and information surrounding the 
discovery of 4 will be disclosed when the work is published. In 
particular, data regarding BET potency and the corresponding 
selectivity would help in the application of 4 as a dual 
CECR2/BPTF probe.  
1, 3 and 5 offer three much needed inhibitors for the CECR2 
bromodomain. Their structurally differentiated chemotypes, and 
an accompanying negative control, provides promise for the 
target validation of CECR2’s bromodomain and the assignment of 
any observed phenotype, although thorough target validation 
would benefit from further equally characterized inhibitors. 
PCAF/GCN5 
P300/CBP-associated factor (PCAF) and general control non-
depressible 5 (GCN5) are two HAT proteins that have been linked 
with diseases spanning across a diverse range of therapeutic 
areas, including oncology,18–20 neuro-degeneration,21,22 HIV 
infection,23–25 and inflammation pathways.26 Despite being 
mutually exclusive proteins, the highly homologous amino acid 
sequence shared between them (~73%) and their bromodomains 
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in particular, suggests targeting one selectively over the other is 
unlikely. 
 By the end of 2015, the PCAF/GCN5 chemical tool 
landscape was limited, with only one PCAF/GCN5 inhibitor having 
been disclosed. Moreover, the reported inhibitor possessed µM 
potency (pIC50 = 5.8), thus requiring further optimization. During 
the past 3 years, multiple PCAF/GCN5 inhibitors and chemical 
probes have been disclosed. 
In 2016, three patent applications from Genentech and 
Constellation Pharmaceuticals were released disclosing a 
number of highly potent PCAF/GCN5 dual inhibitors spanning 
three different chemotypes. Exemplified by compounds 6, 7 and 
single unknown diastereomer 8 (Figure 4a), 27–29 (the most active 
analogues from each series) each chemotype demonstrated 
significant improvements in PCAF/GCN5 potency compared to 
the previously reported PCAF inhibitors.13 Due to the nature of 
patent applications, little is known about the selectivity, 
permeability, solubility and cellular activity of any of the disclosed 
compounds, thus, it is impossible to comment on their ability to 
function as PCAF/GCN5 chemical probes.  
 Developed independently, yet bearing a striking similarity to 
compounds disclosed by Genentech and Constellation 
Pharmaceuticals (e.g. 6)27, researches at GSK published 
GSK4027 (10) as a selective and potent PCAF/GCN5 chemical 
probe (Figure 4b). Starting from a screening of ~30000 known 
and potential acetyl lysine mimetic containing compounds, an 
initial pyridazinone scaffold, demonstrating moderate potency 
(pIC50 = 4.8) and good ligand efficiency (0.37), was optimized by 
iterative SAR to develop 10. X-ray crystallography was used to 
drive the optimization of hit compound 9 and to identify a number 
of hydrogen bond interactions between 9 and the bromodomain 
of PCAF (Figure 4d). These include the expected hydrogen bond 
between the carbonyl group and the side chain NH2 group of 
Asn803, and a shorter water mediated hydrogen bond to Tyr760. 
More interestingly was the observation that the halogen group 
was acting as the methyl mimetic, and not the expected methyl 
group, and the identification of Glu756 as a key acidic residue 
found in the ZA channel, absent in BET bromodomains, from 
which last time I’ll highlight this. Could say..... from which 
high selectivity of 10.... over the BET subfamily was achieved. 
Utilizing a TR-FRET assay, 10 demonstrated good potency 
against PCAF (pIC50 = 7.4) and >1000-fold selectivity over the 
BET subfamily (BRD4(1) pIC50 <4.3). The selectivity of 10 was 
further investigated via a BROMOscan panel ultimately 
confirming 10’s high selectivity, demonstrating ≥18000-fold 
selectivity over the BET family of bromodomains and ≥70-fold 
selectivity over the other remaining bromodomains, with an 
exception of the highly homologous GCN5 where equipotency 
was displayed. Additionally, 10’s selectivity over a collection of 
pharmacologically relevant off-targets was also investigated with 
cross screening against a panel of 53 biochemical and phenotypic 
assays showing no activity <3 µM. 10 possesses good 
permeability (500 nm/s) and solubility (149 µg/mL) and 
demonstrated cellular target engagement of PCAF (pIC50 = 7.2) 
through the use of a NanoBRET assay, providing convincing  
 
Figure 4. a) Structures of PCAF/GCN5 inhibitors 6-8; b) Structures of 
PCAF/GCN5 chemical probe 10, accompanying negative control 11 and initial 
hit compound 9; c) Structures of PCAF/GCN5 chemical probe 13, 
accompanying negative control 14 and initial hit compound 12; d) Crystal 
structure (PDB: 5MLJ) of 10 (grey) bound to human bromodomain GCN5 
(purple); e) Crystal structure (PDB: 5TPX) of 13 (grey) bound to plasmodium 
falciparum bromodomain GCN5 (purple). 
evidence to support its ability to reach the target site. 8 was also 
accompanied by GSK4028 (11) an enantiomeric negative control 
(PCAF pIC50 = 4.9).30  
 Similarly, L-Moses (13), another selective and potent 
PCAF/GCN5 inhibitor, has recently been reported as a chemical 
probe for PCAF/GCN5 (Figure 4c).31 The triazolopyridazine 
scaffold, found in promiscuous bromodomain inhibitor 
bromosporine32, was used as a starting point. Introduction of small 
amine groups were used to exploit the characteristically narrow 
PCAF ZA channel and to establish the acid/base interaction with 
Glu756 discussed previously (Figure 4e), from which selectivity 
over the BET subfamily can be attributed. Differential scanning 
fluorimetry (DSF) identified hit compound 12 from which further 
e) d) 
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iterative SAR was conducted, ultimately resulting in 13. 13 
displayed good potency against PCAF (pKd = 6.9) and GCN5 (pKd 
= 6.2) as demonstrated by isothermal titration calorimetry (ITC). 
Additionally, 13 also displayed good selectivity against BET 
bromodomains (>×4500 over BRD4) and the remaining non-BET 
bromodomains, measured using DSF. 13 is soluble (>72 µg/mL), 
permeable in MDCK-MDR1 cells (100 nm/s), and was shown to 
displace NanoLuc-tagged full-length PCAF from Halo-tagged 
histone H3.3 within cells at 5 µM. A structurally related negative 
control for 13 is reported in the form of its inactive enantiomer D-
Moses (14). 
 The pharmacophore similarity between the molecules 
disclosed by Genentech/Constellation Pharmaceuticals, GSK and 
the SGC is striking. In particular, the HBD separated by two atoms 
from a basic amine and the pendant lipophilic group are seen in 
all the highlighted PCAF/GCN5 inhibitors. This raises concern for 
potential common off-targets and is an issue that will hopefully be 
addressed with new chemotype PCAF/GCN5 chemical probes in 
the future. Additionally, a lack of selectivity between PCAF and 
GCN5 prevents the assignment of any phenotype to a single 
bromodomain, and dissection of their individual roles in 
healthy/disease state modulation. 
BPTF 
BPTF (bromodomain and PHD finger transcription factor), aka 
FALZ, has been identified as an oncology target, being associated 
predominantly with a wealth of cancers such as colorectal,33 
bladder,34 melanoma35 and leukemia.36 A lack of any reported 
BPTF bromodomain inhibitors has resorted in a poor 
understanding of BPTFs role in these diseases. Recently 
however, Urick and co-workers have reported the first BPTF 
bromodomain inhibitor, arylurea AU1 (15) (Figure 5a). A library of 
229 small molecules was screened simultaneously against 
BRD4(1) and the bromodomain of BPTF using protein-observed 
19F-NMR (PrOF NMR), ultimately leading to 15 and two other 
selective hits, with follow up ITC experiments confirming 15’s 
potency (BPTF pKD = 5.6) and selectivity for BPTF over BRD4(1) 
(negligible chemical shift changes at up to 160 µM).  Kinase 
inactivity, and activity in ‘cell culture’ is reported, although, along 
with solubility and permeability, no data is provided. Binding of 
arylurea inhibitors to BPTF has been correlated to a benzene ring 
with a meta-substituted carbonyl. Docking of 15 into the 
bromodomain of BPTF supports this hypothesis, with π-π 
interactions to Phe2887 and hydrogen bonds to Asn2881 
observed, although crystallography is required to confirm this.37,38 
Although substantial further development into BPTF inhibitors is 
required to enable the target validation of BPTF’s bromodomain, 
15 demonstrates the BPTF bromodomain is ligandable with small 
molecules, and acts as a lead molecule for further optimization. 
 
Figure 5. Structure of BPTF inhibitor 15. 
CREBBP/EP300 
CREBBP (CREB binding protein) and EP300 (E1A-associated 
protein p300) are adenoviral E1A-binding proteins involved in 
multiple cellular processes, functioning as HATs and transcription 
co-factors. Since their discovery, both have been implicated in a 
variety of cancers such as prostate cancer,39 acute myeloid 
leukemia,40 and Rubinstein-Taybi syndrome.41 The highly 
homologous bromodomains of these closely related proteins 
suggests individual inhibition of each is difficult. 
 The CREBBP/EP300 chemical tool repertoire is one of the 
most extensive of the non-BET bromodomains. This was the case 
3 years ago during our previous review where two submicromolar 
potency compounds were discussed (pKD = 6.8 & 7.7). Since that 
review, a number of other CREBBP/EP300 inhibitors have been 
developed, including multiple with nM potencies (pIC50 = 8.0-9.2), 
exemplifying the dramatic advancements in the field.  
Crawford and co-workers have reported GNE-272 (17), as 
a potent CREBBP/EP300 inhibitor (Figure 6a). A thermal shift 
assay was used to screen CREBBP against a diverse set of 
compounds with assigned “lead-like” properties.42 Subsequent 
dose response characterization of the most potent hits (ΔTm >1 
ºC) followed, ultimately leading to initial hit compound 16 being 
selected for further optimization, due to possessing good LE 
(0.47) and ~100-fold selectivity over BET bromodomains 
(BRD4(1)). X-ray crystallography identified the N-acetyl group as 
the acetylated lysine mimetic with the amide carbonyl forming a 
hydrogen bond interaction with Asn1168 and water-mediated 
hydrogen bond interactions with Pro1110 and Tyr1125. 
Additionally, van der Waals interactions between the phenyl ring 
and the LPF shelf (Leu 1109, Pro110 and Phe1111) were 
observed, whilst the pyrazolopiperidine core was shown to 
occupy the space between the gatekeeper residue (Val1174) and 
Leu1120. Guided SAR and optimization of permeability and 
mouse liver microsomal stability ultimately delivered compound 
17. 17 demonstrated good potency for CREBBP (CREBBP pIC50 
= 7.7), and 630-fold selectivity over BET bromodomains (BRD4(1) 
pIC50 = 4.9) in a TR-FRET assay. 17’s selectivity against other 
non-BET bromodomains was partially investigated, displaying 
>600-fold selectivity against 10 BCPs. 17 displayed good 
permeability (PappA-B = 150 nm/s) and demonstrated cellular 
activity at submicromolar concentrations (CREBBP pIC50 = 6.4) in 
a NanoBRET assay.  
Since the disclosure of 17, Genentech have optimized the 
scaffold further to produce chemical probe GNE-781 (18) (Figure 
6a). Seeking to further improve potency for CREBBP and 
selectivity over the BET sub-family, the aniline nitrogen of 17 was 
constrained into a bicyclic tetrahydroquinoline (THQ) to further 
disfavour the planar binding conformation adopted by 17 in 
BRD4(1). Additionally, structure-based optimization was utilized 
to target the LPF shelf and BC loop (Figure 6c). Finally, switching 
to a methyl urea acetylated lysine mimetic to introduce an 
additional H-bond donor, and thus reduce CNS penetration, 
resulted in 18.43 As discussed, 18 displayed excellent potency for 
CREBBP (pIC50 = 9.0) and an improved selectivity over the BET 
family (pIC50 = 5.3). Additionally, 18 showed selectivity over the 
non-BET bromodomains (>×5000), as demonstrated by a 
DiscoverX BROMOscan (40 bromodomains) panel, as well as 
against kinase (no inhibition >10% at 1 µM), CEREP off-target (no 
inhibition >39% at 10 µM), and cytochrome p450 (no inhibition at 
1 µM) panels. Target engagement was also demonstrated using 
a NanoBRET assay with 18 displaying excellent potency 
(CREBBP pIC50 = 8.2) and demonstrating cellular permeability. 
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Additionally, 18 was also shown to possess acceptable PK 
parameters in mouse, rat, dog and monkey, offering promise for 
its use within an in vivo setting also. The quality of 18 as a 
chemical probe for CREBBP/EP300 was reflected in the target 
validation accomplished utilizing 18. Inhibition of the CREBBP 
bromodomain was shown to modulate CREBBP-dependent MYC 
expression and supress MOLM-16 tumour growth. Additionally, 
18 was used to confirm the interaction of CREBBP with FOXP3, 
a transcription factor essential for immune homeostasis,44 
providing invaluable target validation of the CREBBP 
bromodomain, and proposing CREBBP bromodomain inhibition 
as a novel avenue for cancer immunotherapy. 
Genentech subsequently demonstrated the transferability of 
the THQ-CF2H pyrazole shelf group, responsible for 18’s 
excellent CREBBP/EP300 potency and selectivity, by designing 
and optimizing two additional CREBBP/EP300 inhibitors, 19 and 
20, with benzimidazolone and azaindole cores respectively. As 
predicted, the CREBBP potency was maintained for both 19 and 
20, along with 300-fold and 1000-fold selectivity over the BET 
bromodomains respectively. Additionally, both compounds 
demonstrated >1000-fold selectivity over other non-BET 
bromodomains and cellular activity within a MYC expression 
assay, with 21 also exhibiting low clearance (18.2 mL min-1 kg-1) 
and moderate bioavailability (52%) in mice.45  
Using SGC-CBP30 (21) as a start point, Pfizer have 
developed PF-CBP1 (22) (Figure b) through the use of structural 
based design with existing CREBBP and BRD4 crystal structures 
(Figure 6d).46 22 showed good potency for CREBBP (pIC50 = 6.9) 
and weak BRD4(1) potency (pIC50 = 4.7), revealing a >100-fold 
selectivity. The benzoimide N-3 nitrogen was shown to form a 
water mediated hydrogen bond interaction with Pro82 in BRD4. 
Therefore, to further improve CREBBP/EP300 selectivity, the 
benzimidazole core of 22 was converted to an azoindole group in 
an attempt to remove this interaction and point the nitrogen 
towards solvent, ultimately leading to PF-CBP2 (23). 23 also 
showed good potency for CREBBP (pIC50 = 6.9) and weak 
BRD4(1) potency (pIC50 = 4.7). Additionally, 23 was also 
screened against a further 30 bromodomains using the DiscoverX 
BROMOscan panel with good selectivity being observed 
throughout, excluding BAZ2A (>80% inhibition at 10 µM), 
although no KD values have been determined. Additionally, a 
clean polypharmacology profile (pIC50 <5.0) was also observed 
across a 19 component CEREP panel. Although 23 appears  
 
Figure 6. a) Structure of CREBBP chemical probes 17 and 18, initial hit 
compound 16 and additional CREBBP inhibitors 19 and 20; b) Structures of 
CREBBP inhibitors 21-24; c) Crystal structure (PDB: 5W0E) of 18 (grey) bound 
to human bromodomain CREBBP (yellow); d) Crystal structure (PDB: 4NR7) of 
21 (grey) bound to human bromodomain CREBBP (yellow). 
permeable (68 nm/s) no cellular activity data is reported. 
Furthermore, measured KDs for the most active bromodomains at 
10 µM, in particular BAZ2A, would help confirm 23’s selectivity 
and thus any phenotypic assignment from the probe. Pfizer also 
demonstrated the potential for N-ethyl pyridinone warheads, and 
from their photoaffinity probe work,47 tropolone mimetics such as 
c) d) 
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24, helping to expand the SAR further and offering new avenues 
for CREBBP/EP300 chemical probe development. 
Two CREBBP/EP300 inhibitors have been discovered by 
Xiang and co-workers, based around a 1-(1H-indol-1-yl)ethanone 
chemotype (Figure 7a).48 Commencing with a fragment based 
virtual screen, fragment 25 was subsequently optimized to deliver 
inhibitor 26 utilizing X-ray crystallography driven SAR. The 
carbonyl of the carboxyl group was shown to form a water 
mediated hydrogen bond to Arg1173 and vital to CREBB potency. 
Thus, an amide linker and an aromatic ring were introduced to 
increase the rigidity of the chain and optimize this interaction. 
Utilizing an Alpha screen assay, 26 was shown to demonstrate 
good potency for CREBBP (pIC50 = 7.4) and to be highly selective 
over the BET subfamily (pIC50 < 4.7) and a selection of five other 
non-BET bromodomains (all pIC50 < 4.7). Although no 
permeability or solubility data is reported, a lack of inhibition effect 
against LNCaP and 22Rv1 cells is attributed to poor cellular 
permeability, due to the highly polar carboxyl group. 
Consequently, ester derivative 27 was synthesized and 
demonstrated reasonable potency for CREBBP in biochemical 
(pIC50 = 6.4) and cellular (pIC50 = 5.7) assays. Compound 26 
poses itself as a new chemotype for CREBBP/EP300 inhibitor 
development but would benefit from further selectivity 
characterization, in particular against other non-BET 
bromodomains and pharmacological off-targets. Additionally, it is 
unclear whether 27 itself is the active species responsible for 
inhibition of CREBBP within the cellular assay, or if the ester is 
hydrolyzed within the cells to generate 26 in a prodrug fashion. 
XDM-CBP (29) has also been published as an inhibitor of 
CREBBP/EP300, optimised from the core fragment structure (28) 
of recently published BET inhibitor XD14 (Figure 7b).49 Utilizing 
a combination of computational methods, along with X-ray 
crystallography and ITC, 29 was developed with micromolar 
potency for CREBBP (pKD = 6.6) and good selectivity (×150) over 
BET bromodomains (BRD4(1) pKD < 4.4). Key to this drop in BET 
potency was the introduction of hydroxy groups to the 
naphthalenyl ring which provided additional intramolecular 
hydrogen bonds (Figure 7d), and consequently an increased 
rigidity, making the conformational change to adapt to the 
acetylated lysine binding site of BRD4(1) energetically 
disfavoured. 29 appeared selective (>×40) against a 40 
bromodomain DiscoverX bromoKdELECT assay, with the 
exception of BRD7 (BRD7 pKD = 5.3) and BRD9 (BRD9 pKD = 
5.5) where 10-fold selectivity was observed. Selectivity against 
pharmacologically relevant off-targets is currently unknown for 30, 
as is the potential for cellular activity at submicromolar 
concentrations. Nevertheless, 29 provides a promising ligand 
efficient (LE = 0.33) fragment for future optimization. 
Further optimization around a previously reported CREBBP 
inhibitor, I-CBP112 (30),50 has led to the discovery of TPOP146 
(31) (Figure 7c & e).51 Starting from an initial library of 48 2,3,4,5-
tetrahydro-1,4-benzoxazepine scaffold containing compounds, 
DSF was utilized to identify the racemate of previously discussed 
inhibitor 30 as an initial hit compound. Comprehensive SAR 
investigation around the 2,3,4,5-tetrahydro-1,4-benzoxazepine  
 
 
Figure 7. a) Structure of CREBBP inhibitors 26 and 27, and initial hit compound 
25; b) Structure of CREBBP inhibitor 27 and initial hit compound 28; c) Structure 
of CREBBP inhibitor 31 and starting point 30; d) Structure of CREBBP inhibitor 
33, accompanying negative control 34 and initial hit compound 32; e) Crystal 
structure (PDB: 5NU5) of 29 (grey) bound to human bromodomain EP300 
(yellow); f) Crystal structure (PDB: 5J0D) of 31 (grey) bound to human 
bromodomain CREBBP (yellow); g) crystal structure (5I8G) of 33 (grey) bound 
to human bromodomain CREBBP (yellow). 
scaffold ultimately led to 31. Using ITC, 31 demonstrated potency 
for CREBBP (pKD = 6.9) and 30-fold selectivity over BRD4(1) (pKD 
e) f) 
g) 
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= 5.3). Furthermore, 31 appeared selective against a further 44 
bromodomains when investigated via DSF, although it should be 
noted, DSF varies from protein to protein and as such should be 
treated with caution. Cellular activity was demonstrated using a 
modified FRAP assay, in which 1 µM concentrations produced a 
reduced recovery half-life. Despite improved non-BET 
bromodomain selectivity compared to 30, again, only moderate 
selectivity over the BET subfamily limits the applicability of 
benzoxazepine CREBBP/EP300 inhibitors. 
CPI-637 (33), a CREBBP/EP300 inhibitor based around a 
benzo[1,4]-diazepin-2-one scaffold, has been reported by 
Genentech and Constellation Pharmaceuticals (Figure 7d).52 A 
fragment screening of ~2000 compounds in a thermal shift assay 
was utilized to identify hit compound 32, chosen for displaying 
potency at CREBBP (pIC50 = 4.5) and 7-fold selectivity over the 
BET subfamily. X-ray crystallography identified the lactam portion 
of the benzo[1,4]-diazepin-2-one to be functioning as the KAc 
mimetic, with the expected hydrogen and water mediated 
hydrogen bond interactions to the conserved Asn and Tyr 
respectively observed. An additional hydrogen bond interaction 
was also observed between the lactam NH and the carbonyl of 
the conserved Asn (Figure 7g), whilst the 4-methyl group was 
shown to occupy the hydrophobic binding pocket. Substitution at 
the 6 position with indazoles was shown to fill space above 
Pro1110 and the Pro/Arg cleft to provide additional hydrophobic 
interactions and an accompanying boost in CREBBP potency, 
eventually leading to 33. 33 showed potency at CREBBP (pIC50 = 
7.5) and >200-fold selectivity over the BET subfamily and 6 other 
non-BET bromodomains. Activity was however observed against 
BRD9 (pIC50 = 6.1). Moreover, 33 demonstrated potency for 
CREBBP within a cellular assay (pIEC50 = 6.5) and was 
accompanied by a structurally related negative control (CREBBP 
pIC50 = 5.5) in the form of its opposite enantiomer. No data on 
other pharmacological off-targets is provided, and further non-
BET selectivity characterization would be beneficial.  
The discussed compounds add extra value and increased 
diversity to the already extensive CREBBP/EP300 chemical 
probe tool box. In particular, 18 offers a step change in potency 
and BET selectivity from previously disclosed CREBBP/EP300 
probes. The advanced CREBBP/EP300 tool box for target 
validation is also reflected in the number of recently disclosed 
CREBBP therapeutic patents (Figure 8). Genentech and 
Constellation Pharmaceuticals have released three patents 
disclosing a range of CREBBP/EP300 inhibitors based around the 
tetrahydro-pyrazolopyridine scaffold seen previously, and a 
dihydro-benzodiazepinone group. The most potent compound of 
each chemotype, 35 and 36, are shown as representative 
examples.53–55 35 displays excellent potency for CREBBP (pIC50 
= 9.1) and is reported to be active within a cellular MYC assay 
(pIC50 = 8.1). Similarly, 36 shows excellent potency for CREBBP 
(pIC50 = 9.2) and is active within a cellular MYC assay (pIC50 = 
8.0). Additionally, BET potency data is reported for 36, 
highlighting its high selectivity (×1000). Similar data is reported for 
37 which is also potent at CREBBP in biochemical (pIC50 = 8.5) 
and cellular MYC assays (pIC50 = 8.0) and is selective (×1000) 
over the BET subfamily. Due to the nature of patents, however,  
 
Figure 8. a) Structure of reference patented CREBBP inhibitors 35-37; b) 
Structure of reference patented CREBBP inhibitors 38-40; c) Structure of 
reference patent CREBBP inhibitor 41; d) Structure of reference patent 
CREBBP inhibitor 42. 
no further information is provided for either compound. Likewise, 
Cellcentric have released two patents on CREBBP/EP300 
inhibitors based around triazole and isoxazole KAc mimetics.56,57 
A representative example of each chemotype, 38 and 39, are 
shown. Although no data was provided, both are reported to have 
potencies between 100 nM-100 µM. A patent on CREBBP/BRD4 
dual inhibitors was also released by Celgene disclosing a range 
of CREBBP inhibitors.58 Although no specific potency data was 
disclosed, ranges of potency were provided and a selective 
CREBBP example 40 is shown. Stanford Junior University have 
also disclosed a number of CREBBP/EP300 inhibitors via patent 
application, in which ranges of cell viability data were disclosed 
against three cell lines (HL60, Jukat and Nalm6).59 41 was chosen 
as a representative example, displaying pIC50 >7 in Jukat and 
Nalm6 cell assays and a pIC50 >6 in HL60 cell assay. Finally, a 
patent disclosing a wealth of CREBBP/EP300 inhibitors was 
released by the University of Zurich.60 The most potent CREBBP 
inhibitor (CREBBP pKD = 7.1) 42 is shown as a representative 
example. 
 
 
 
BRPF1/2/3 
Some of the more well understood non-BET BCPs are the 
bromodomain and PHD finger-containing protein family 
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(BRPF1/2/3). BRPF1/3 & BRPF2 (aka BRD1) are a group of 
paralogs found within HAT complexes which have been predicted 
play a critical role in acute myeloid leukemia.61,62 This improved 
understanding of BRPF1/2/3 and the relatively advanced target 
validation of their bromodomains is reflected in the sophisticated 
portfolio of effective chemical probes available.  
At the time of our previous review, the BRPF1/2/3 chemical 
probe tool box was already well established with several potent 
inhibitors (pKD = 7-8) being disclosed, typically bearing a dimethyl 
imidazolidinone scaffold. Since then a multitude of additional 
BRPF1/2/3 inhibitors have been published, again built around the 
same dimethyl imidazolidinone scaffold which continues to 
dominate the BRPF1/2/3 chemical probe landscape. Despite little 
to no advances in potency and diversity, the selectivity of 
BRPF1/2/3 inhibitors has improved, selectivity over the BET 
subfamily, but also within the BRPF paralogs. 
One of the more recent additions to the BRPF1/2/3 chemical 
probe tool box is GSK6853 (44), a potent and highly selective 
BRPF1 bromodomain inhibitor optimized from the previously 
reported BRPF1 inhibitor GSK5959 (43).63 In optimizing 43 to 44, 
GSK improved the solubility from 8 µg/mL to 140 µg/mL, and 
consequently improved its applicability to in vivo experiments.64,65 
This was achieved through the introduction of a basic nitrogen at 
the 6-position of the piperidine ring, improving the compounds 
physicochemical properties whilst in turn forming a hydrogen 
bond to Asn651 carbonyl to maintain potency, as predicted by X-
ray crystallography (Figure 9e). Further interrogation of the 
crystal structure presented the 2-position of the piperidine ring as 
a vector towards Pro658, one of only a few residues not 
conserved between the BRPF family, where a favourable 
interaction with a methyl group was harnessed for improved 
BRPF1 potency (pIC50 = 8.1) and BRPF sub family selectivity 
(BRPF2 = ×1000 and BRPF3 >×1000). Moreover, 44 retained its 
high selectivity over BET bromodomains (>×1600) as measured 
by TR-FRET assay and was selective (>×2000) against a further 
26 non-BET bromodomains in the DiscoverX BROMOscan panel. 
Additionally, 44 displayed selectivity (×500) against a cross 
screen panel of 48 pharmacologically relevant off targets 
including kinases, ion channels, GPCRs, enzymes, transporters 
and a nuclear receptor. The cellular activity of 44 was then 
demonstrated using a NanoBRET assay where potent inhibition 
(BRPF1 pIC50 = 7.7) was displayed. Along with GSK9311 (45), a 
structurally related negative control, 44 shows good potential for 
use as a chemical probe of BRPF1. Furthermore, 44 also 
possesses suitable PK for in vivo mouse studies following 
intraperitoneal delivery.  
 Collaborative work between Bayer and the SGC has led to 
the identification of BAY-299 (47), a potent and selective triple 
inhibitor of BRPF2 (BRPF2 pIC50 = 7.2) and TAF1/TAF1L (TAF1 
pIC50 = 8.1).66 An initial HTS of ~3.5 million compounds resulted 
in potent (BRPF2 pIC50 = 6.3) hit compound 46, selected for 
displaying selectivity over BRD4 (BRD4(1) pIC50 = 4.9). 
Optimization of potency, solubility, in vitro DMPK and selectivity  
 
 
Figure 9. a) Structure of BRPF1 chemical probe 44, accompanying negative 
control 45, and starting point 43; b) Structure of BRPF1/TAF1 dual inhibitor 47, 
accompanying negative control 48, and hit compound 46; c) Structure of BRPF1 
inhibitor 50 and initial hit compound 49; d) Reference patent BRPF1 inhibitor 51; 
e) Crystal structure (PDB: 5G4R) of 44 (grey) bound to human bromodomain 
BRPF1 (cyan); f) Crystal structure (PDB: 5N49) of 44 (grey) bound to human 
bromodomain BRPF2 (cyan); g) Crystal structure (PDB:5MWH) of 50 (grey) 
bound to human bromodomain BRPF1 (cyan). 
resulted in 47, with a key interaction between a carbonyl group 
and Ser592 providing the desired BRPF2 selectivity (Figure 9f). 
47 was shown to engage BRPF2 (BRPF2 pIC50 = 7.2) selectively 
over BRPF1 (BRPF1 pIC50 = 5.5) and BRPF3 (BRPF3 pIC50 = 
5.3) as measured by a TR-FRET assay. 47 also demonstrated 
selectivity over the BET subfamily (BRD4 pIC50 = 4.8), >300 
kinases (<50% inhibition in all cases at 10 µM) and against a 
LeadProfilingScreen containing 68 pharmacologically relevant 
e) f) 
g) 
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targets (<25% inhibition in all cases at 10 µM). Selectivity was 
also demonstrated against 32 bromodomains in an alpha screen 
assay excluding CREBBP where at 100 nM modest CREBBP 
potency was shown (CREBBP pIC50 = 5.8). 47 demonstrated 
permeability (Caco2 cell Papp = 163 nm/s) and was shown to 
successfully engage BRPF2 (pIC50 = 6.3) and TAF1(2) (pIC50 = 
6.0) within cells, as measured by NanoBRET assay, despite poor 
solubility (10 µg/mL). A structurally similar negative control, BAY-
364 (48), was also developed and showed reduced potency at 
both BRPF2 (BRPF2 pIC50 <4.7) and TAF1 (TAF1 pIC50 = 4.9). 
The polypharmacology of 47, however, hinders assigning any 
observed phenotype to a particular bromodomain. Bayer have 
subsequently published a patent disclosing a number of other 
BRPF1/TAF1 dual inhibitors based around the same dimethylated 
imidazolidinone core scaffold.67 
 In a deliberate attempt to expand the variety of chemotypes 
involved in BRPF1 inhibitors, Caflisch and co-workers developed 
50.68 An initial fragment based pharmacophore search identified 
hit compound 49. Molecular docking and a subsequent 
substructure search around the 1,4-dimethylquinoxaline-2,3-
dione scaffold ultimately led to 50. X-ray crystallography was used 
to identify key hydrogen bond interactions to the conserved Asn 
(Asn708), Cys704, and a water mediated hydrogen bond 
interaction to the conserved Tyr (Tyr665) (Figure 9g). Additionally, 
the phenyl ring of 50 was shown to form an edge-to-face π-π 
interaction to Phe714, the gatekeeper residue found in BRPF1’s 
bromodomain, whilst the morpholine group forms a water 
mediated hydrogen bond to Gly650. 50 displayed potency at 
BRPF1 in Alpha screen (pIC50 = 5.7) and BROMOscan assays 
(pKD = 5.7). ‘Negligible activity’ against the BET subfamily (BRD4), 
BRPF2/3, ATAD2 and CREBBP is reported for 50, although no 
data is provided. Alternatively, activity against BRD9 is reported 
(BRD9 pIC50 = 3.7). No cellular activity data is reported for 50 and 
a negative control is not provided. 50 would benefit from further 
selectivity characterization, in particular against other non-BET 
bromodomains and pharmacologically relevant off targets, 
however does offer another BRPF1 inhibitor pharmacophore. 
 A patent released by UCL business PLC discloses a range 
of BRPF1 inhibitors based around a quinolinone scaffold.69 A 
representative example, 51, which displays potency for BRPF1 
(pKD = 8.1) is shown. Due to the nature of patents little extra data 
is provided, although potency against BRPF2 (pKD = 7.3), BRPF3 
(pKD = 6.6), BRD7 (pKD = 7.1) and BRD9 (pKD = 6.5) is disclosed. 
 In combination with previously reported BRPF1/2/3 probes, 
44, and 47 help to expand the repertoire of BRPF1/2/3 chemical 
tools for target validation. Moreover, 47 offers promise for BRPF2 
isoform selectivity, which along with BRPF3, remains an 
opportunity for probe development. Additionally, 50 provides hope 
for the development of BRPF1 inhibitors of varying chemotypes 
to help diversify the BRPF1/2/3 chemical tool repertoire, currently 
dominated by the dimethylated imidazolidinone scaffold. 
 
 
 
Figure 10. a) Structure of BRD7/9 chemical probe 53 and 54, accompanying 
negative control 55 and initial hit compound 52; b) Structure of BRD7/9 chemical 
probe 56 and accompanying negative control 57; c) Structure of BRD7/9 
chemical probe 60, intermediate 59 and starting point 58; d) Crystal structure 
(PDB: 5F1H) of 53 (grey) bound to human bromodomain BRD9 (red). 
BRD7/9 
Two BCPs with a repertoire of existing chemical probes are BRD7 
and BRD9. BRD7/9 have both been implicated in the chromatin 
remodelling SWI/SNF complex and the PBAF/BAF complexes in 
humans respectively, each involved in the regulation of gene 
expression, making them promising targets for anti-cancer 
agents.70 More specifically, BRD7 has been shown to function as 
a tumour suppressor across various cancers,71–73 whilst BRD9 
has been found to be involved in cancers through mutation or 
overexpression.74  
 At the end of 2015, the BRD7/9 chemical probe repertoire 
was already well developed including multiple dual BRD7/9 
inhibitors and BRD9 selective inhibitors. In contrast, there were 
no disclosed BRD7 selective inhibitors or promise for future 
d) 
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development. Since then, a variety of new BRD7/9 inhibitors have 
been developed expanding the already diverse library. 
Additionally, a new chemical tool for BRD9 has been developed 
in the form of the first BRD9 PROTAC. 
Collaborative work between the SGC and Boehringer 
Ingelheim has led to the development of BI-9564 (53), an in vivo 
capable potent and selective probe for both BRD7 and BRD9.75 A 
fragment based screening approach utilizing a DSF assay to 
identify initial hits, such as 52, was followed by structure guided 
design, leading to dual BRD7/9 inhibitors 53 and 54 (Figure 10a 
& d). 53 displayed potency for BRD9 (pKD = 8.2) and BRD7 (pKD 
= 7.1), and selectivity over the BET subfamily (BRD4(1) pKD <5.0), 
as measured by a DiscoverX BROMOscan assay. With the 
exception of CECR2 (pKD = 7.1), 53 was also shown to be 
selective against the remaining non-BET bromodomains showing 
no activity at the concentrations tested by ITC. The cellular activity 
of 53 was demonstrated at 1 µM in a FRAP assay using a green 
fluorescent protein-BRD9 fusion protein expressed in U2OS cells. 
53 was also screened against 55 GPCRs and 324 kinases with 
only 2 GPCRs and 3 kinases showing >40% crtl inhibition at 10 
µM. Additionally, 53’s ability to function as an in vivo tool is 
supported by aqueous solubility (>90 µg/mL) and permeability 
(Caco2 Papp = 110 nm/s), and suitable PK within a mouse model 
following intravenous delivery. Likewise, 54 displayed 
subnanomolar potencies for BRD7 (pKD = 9.5) and BRD9 (pKD = 
9.1) with selectivity over the BET subfamily (BRD4(1) pKD < 4.7) 
as demonstrated by DiscoverX BROMOscan assay. Again, 54 
appeared selective against the remaining non-BET 
bromodomains (>30-fold) with potency also observed for CECR2 
(pKD = 8.1). 54 was also shown to engage both BRD7/9 with 100% 
inhibition at 1 µM in FRAP assays, demonstrating target 
engagement and cellular permeability (Caco2 Papp = 14 nm/s), 
and is accompanied by suitable PK parameters within a mouse 
model following intravenous delivery. Finally, 53 and 54 are 
accompanied by negative control BI-6354 (55), although the 
structural differences should be acknowledged.76 
TP-472 (56), another potent and selective BRD7/9 probe, 
has recently been developed by the SGC and Takeda with a novel 
BRD7/9 binding chemotype (Figure 10b). 56 reports good 
potency for BRD7 (BRD7 pKD = 6.5) and BRD9 (BRD9 pKD = 7.5) 
and >×30 selectivity over the remaining bromodomains. Although 
no solubility or permeability data is supplied, 56 cellular activity 
was demonstrated (BRD9 pEC50 = 6.5) in a BRD9 NanoBRET 
assay. A negative control, TP-472N (57), is also reported as being 
inactive against BRD9 at 20 µM, although the large structural 
differences should be considered. No data on the selectivity of 56 
against other pharmacological off-targets is provided.77  
Starting from the N-methyl pyrrolopyridone 58, Crawford 
and co-workers substituted the N-methyl group for a selection of 
small hydrophobic substituents (Figure 10c). The introduction of 
hydrophobic substituents was shown to induce a narrow 
hydrophobic channel in the binding pocket of BRD9.78 
Substitution of the N-Methyl group for a crotyl group (59) reduced 
the potency for BRD4, BRPF1, CECR2, CREBBP and TAF1,  
 
Figure 11. a) Structures of BRD7/9 fragments 61-65; b) Structure of reference 
patented BRD7/9 inhibitors 66-68; c) Structure of BRD7/9 PROTAC 69; 
whilst maintaining submicromolar potency for BRD9 (pIC50 = 6.8). 
Although potency at BRD4 (pIC50 = 6.3) was reduced, only 
moderate selectivity was observed. 59 was then subject to lead 
optimization efforts, focussing primarily on occupying accessible 
space in the ZA channel through para substitution of the benzene 
ring. Additionally, substitution off the ortho and meta positions of 
the benzene ring was hypothesised to occupy a small pocket in 
BRD9, further enhancing selectivity, eventually leading to GNE-
375 (60).79 60 exhibited potency at BRD9 (pIC50 = 8.3) and >3000-
fold selectivity over the BET bromodomains (BRD4(1) pIC50 = 
<4.7) as measured by TR-FRET assays. Potency (BRD9 pKD = 
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8.7) and selectivity against other non-BET bromodomains was 
also confirmed using a BROMOscan panel with >1500-fold 
selectivity observed against the panel, excluding the highly 
homologous BRD7 (pKD = 7.0) where 50-fold selectivity was 
observed. 60 was also screened against an Invitrogen 40 kinase 
panel where no inhibition >20% was observed at 1 µM, and a 
CEREP panel where activity was observed against a GABBA 
receptor (86% at 10 µM). 60 demonstrated target engagement in 
a cellular thermal shift assay (44-50 °C), albeit at 2 µM. After 
demonstrating cellular viability, 60 was then used in the target 
validation of BRD9 bromodomain inhibition. RNA sequencing 
analysis of gene expression following a 24-hour treatment with 60 
showed inhibition of 7 genes. Of note was the inhibition of 
ALDH1A1, an enzyme whose levels and activity have been shown 
to be increased in crizotinib resistant gastric cancer lines.80 
ALDH1A1 and its promoter are regulated by acetylation, 
suggesting BRD9 could play an active role in either/both of these 
mechanisms and proposes a new area for therapeutic 
intervention strategies.  
NMR fragment-based screening has been used to discover 
five ligand efficient fragments (61-65) for future BRD7/9 inhibitor 
optimization (Figure 11a). Of particular interest is bromo pyrazole 
fragment 62 which appears to show ×2.5 selectivity for BRD7 over 
BRD9 and potential for the development of selective BRD7 
bromodomain inhibitors.81  
Numerous patents disclosing BRD7/9 inhibitors have also 
been published since the last review. Following on from their work 
developing BRD7/9 chemical probes, Genentech and 
Constellation Pharmaceuticals have disclosed five additional 
BRD7/9 inhibitors based around the pyrolopyridinone scaffold 
discussed above.82 BRD9 potency (pIC50 = 7.4) and selectivity 
data is reported (200-fold selectivity over the BET subfamily of 
bromodomains and 400-fold selectivity over 7 representative non-
BET bromodomains) for one compound, although the structure is 
not specified. Due to the nature of patents no further data is 
provided. 
Similarly, Boehringer Ingelheim have released a patent 
disclosing numerous BRD9 inhibitors spanning three different, 
albeit related, chemotypes. Cellular activity data in either a BRD9 
H3 or BRD9 H4 assay is provided, and the most potent of each 
chemotype 66 (BRD9 pIC50 = 8.5), 67 (BRD9 pIC50 = 8.3) and 
atropisomer 68 (BRD9 pIC50 = 7.4) are included for reference. All 
three chemotypes show potency for BRD9 and cellular target 
engagement, however no further characterization is provided.83 
Bradner and co-workers have disclosed dBRD9 (69) the first 
BRD9 PROTAC.84 A selection of BRD9 PROTACs were 
synthesised based around three different BRD9 chemical probes, 
LP99, I-BRD9, both of which were reviewed previously,13 and 54 
discussed above. 54 was eventually chosen to function as the 
selective BRD9 inhibitor part of the PROTAC, due to improved 
BRD9 selectivity (in particular selectivity over the BET subfamily) 
when compared to LP99 and I-BRD9 PROTAC derivatives, 
highlighting the advances that have been made in BRD9 chemical 
probe development since our last review. To complete the 
bifunctional PROTAC, an E3 ligase recruiter (a pomalidomide 
conjugate) was appended via a poly-ethylene glycol (PEG) to 
produce 69. 69 maintained potency for BRD9 (pIC50 = 7.0) and 
selectivity over the BET subfamily (BRD4(1) pIC50 < 4.3). BRD9 
was selectively degraded over a range of potencies using 69 
(BRD9 pDC50 = 7.0). The cellular selectivity of 69 was then 
demonstrated using MOLM-13 cells, in which, out of the 7326 
proteins quantified, only BRD9 showed a statistically significant 
difference in abundance (5.5-fold decrease after treatment with 
100 nM of 67 for 2 hours). A control species for 69 was generated 
through the removal of the acetylated lysine mimetic, thus 
removing any potency for BRD9 (pIC50 < 5). Interestingly, both 69 
and its inactive negative control retained activity against the IKZF 
family of transcription factors and should be accounted for when 
using 69 for target validation. The development of non-BET 
bromodomain PROTACs will help expand the target validation of 
these proteins into the effects of degradation in comparison to 
bromodomain inhibition. 
The discussed BRD7/9 inhibitors help expand the BRD7/9 
chemical tool repertoire, both in quantity and diversity, although 
there still appears to be a reliance on bi-aryl scaffolds in the 
pursuit of selective BRD7/9 probes. Along with the existing 
BRD7/9 selective chemical probes, and introduction of a new 
BRD9 degrader, target validation for the bromodomains of 
BRD7/9 and dissection of the individual roles of each proteins 
bromodomains, shows promise, one omission being the absence 
of a selective BRD7 probe.  
ATAD2/ATAD2B 
ATAD2 and ATAD2B are chromatin remodelling proteins which 
consist of an AAA+ ATPase domain and a highly homologous 
(76% consistent amino acid sequence) bromodomain. Both 
proteins have been strongly linked with a diverse range of cancers 
including lung,85 liver,86 prostate and breast, hence the desire for 
ATAD2/ATAD2B chemical probes for further target validation.87, 88 
At the end of 2015, the ATAD2/ATAD2B chemical repertoire was 
in its infancy, with one optimized ATAD2/ATAD2B inhibitor 
disclosed, which unfortunately showed activity against 
TAF1/TAF1L. Since then, the ATAD2/ATAD2B chemical tools 
available have grown, with the first ATAD2/ATAD2B chemical 
probe, and ATAD2 isoform selective chemical probe being 
developed.  
GSK have reported ATAD2 chemical probe, GSK8814 (72), 
optimized from their previously reported ATAD2 inhibitor (71) 
(Figure 12a).89 Of note was the substitution of the sulfone group 
for the more polar -CF2 bioisostere which provided a needed 
increase in permeability, along with an increase in solubility. 
Secondly, 1,3-interactions on the piperidine ring were utilized to 
destabilise the axial conformation favoured for BRD4(1) binding, 
thus improving selectivity over the BET subfamily (Figure 12d). 
69 demonstrated potency for ATAD2/2B (ATAD2/2B pIC50 = 
7.3/7.7) with selectivity over the BET family (>×1000) and other 
non-BET bromodomains (×100). Cellular target engagement of 66 
with ATAD2 (pIC50 = 5.7) was demonstrated using a NanoBRET 
assay and was reflected in the solubility (2313 µg/mL) and 
permeability (190 nm/s) of 72. Moreover, 72 was screened 
against an internal GSK panel of 40 pharmacological off-targets 
and was inactive at the concentrations tested. The corresponding 
enantiomer of 69, known as GSK8815 (73), displayed a reduced 
potency for ATAD2/2B (pIC50 = 5.5/5.5) and provides an 
enantiomeric negative control for phenotypic screening.90 
An alternative conformation locking strategy for disfavouring 
BRD4(1) binding has also been reported by GSK utilizing a 
tropane group in place of the piperidine ring.91 As discussed 
above, forcing the polar shelf group into an equatorial position, as 
seen with tropolone derivatives, strongly favours ATAD2 (pIC50 = 
6.6) binding over BRD4(1) (pIC50 < 4.3) resulting in an improved 
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selectivity (>250-fold). As a result, 74 provides further evidence to 
support the development of BET selective ATAD2 chemical 
probes through conformational locking. 
 Bayer have recently reported BAY-850 (76), the first ATAD2 
isoform selective inhibitor. An initial screening of 11 DNA 
encoding chemical libraries, amounting to ~65 billion compounds, 
resulted in hit molecule 75.92 The two stereogenic centres were 
quickly identified as crucial for ATAD2 potency and optimization 
was focussed primarily on the methyl amide, with substitution for 
a more lipophilic and basic cyclohexyl diamine providing the 
required potency boost. 76 showed good potency for ATAD2 (pKD 
= 6.9) and selectivity against a wide range of other BET and non-
BET bromodomains (31 DiscoverX BROMOscan panel), with only 
BRD3(1) and BAZ2B showing greater than 50% inhibition at 10 
µM. Similarly, 76 appeared selective against a panel of 354 
kinases and 25 GPCRs with only modest potency shown for a few 
GPCRs. Solubility (>3070 µg/mL) and permeability (39 nm/s) 
were also reported for 76 which, as a result, successfully 
demonstrated cellular activity at 1 µM via a FRAP assay as 
evidence of target engagement. Uniquely amongst published 
ATAD2 inhibitors, 76 appears selective over ATAD2B, suggesting 
a different mode of binding to that of the previously discussed 
ATAD2 inhibitors. Through the use of mass spectrometry and size 
exclusion chromatography, Bayer identified that 76 
simultaneously binds two ATAD2 molecules to form a dimer 
complex. Moreover, 76 was accompanied by structurally related 
negative control BAY-460 (77), which together function as unique 
ATAD2 inhibitors for target validation. 
Finally, Miller and co-workers have reported 79 as a novel 
ligand for ATAD2 inhibitor development (Figure 12c). Initial hit 
fragment 78 was identified via crystallographic fragment  
 
 
Figure 12. a) Structure of ATAD2/ATAD2B chemical probe 72, accompanying 
negative control 73, starting point 71 and additional inhibitor 74; b) Structure of 
ATAD2 chemical probe 76, accompanying negative control 77 and initial hit 
compound 75; c) Structure ATAD2/ATAD2B inhibitor 79 and initial hit compound 
78; d) Crystal structure (PDB: 5LJ0) of 72 (grey) bound to human bromodomain 
ATAD2 (blue). 
screening as a weak ATAD2 inhibitor. Interestingly, methylation 
of the pyrrolodinone lactam resulted in a change in binding mode 
to ATAD2, with the pyrrolodinone lactam functioning as the 
d) 
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acetylated lysine mimetic. Further structure guided optimization 
resulted in 79 which showed weak potency for ATAD2 (pKD = 4.0) 
and 10-fold selectivity over the BET subfamily. 79 offers potential 
for future ATAD2 inhibitor development following further 
optimization.93 
 76 and 79 provide new inhibitors and chemotypes for future 
ATAD2 chemical probes. Additionally, 72 expands on an existing 
chemotype to deliver a high quality ATAD2 chemical probe. When 
combined with the existing array of ATAD2 inhibitors target 
validation of ATAD2’s bromodomains looks promising. 
Additionally, the promise of achieving isoform selective 
ATAD2/ATAD2B inhibitors bodes well for dissecting their 
individual roles in disease.  
TRIM24 
Tripartite motif-containing 24 (TRIM24) is a transcription 
coregulator whose over expression has been correlated to a 
wealth of different cancers.94–96 Our previous review concluded 
with the disclosure of two dimethylated imidazolidinone TRIM24 
inhibitors, both of which reported activity at the BRPF subfamily 
of bromodomains. Since then, it has been shown that inhibition of 
TRIM24’s bromodomain fails to exert an effective anti-proliferative 
response, thus suggesting that bromodomain inhibition alone is 
insufficient for anti-cancer therapeutic development.97 As a result, 
no further TRIM24 inhibitors have been disclosed for use as 
chemical probes, instead work has begun into the development of 
more sophisticated TRIM24 chemical tools.   
Bradner and co-workers disclosed dTRIM24 (81), the first 
TRIM24 PROTAC and degrader (Figure 13a).98 Starting from a 
derivative of previously reported TRIM24 chemical probe IACS-
9571 (80), a VHL E3 ligase inhibitor was appended via a PEG 
linker to create bifunctional molecule 81. Bifunctional molecule 81 
displayed similar potency to TRIM24 inhibitor 80. Likewise, a 
similar selectivity profile was observed for 81 against a panel of 
32 bromodomains, with equipotency shown against BRPF1 and 
BRPF2. Cellular permeability was also demonstrated via a VHL 
degron displacement assay, providing evidence of target 
engagement. Importantly, 81 was shown to solely degrade 
TRIM24 (despite selectivity concerns with BRPF1/2) substantially 
at 4 hours and degradation was maintained over 72 hours. 
Whereas TRIM24 inhibitors have been shown to display no anti- 
proliferative phenotype in the treatment of leukaemia, tumours of 
hematopoietic origin were sensitive to degradation of TRIM24, 
highlighting TRIM24 as a novel target for acute leukaemia 
therapeutics. 
Introduction of a TRIM24 PROTAC to the TRIM24 chemical 
tool repertoire offers a unique form of target validation through 
TRIM24 degradation. 81 also demonstrates that partially selective 
inhibitors can produce selective degraders yet highlights the 
importance for high quality chemical probes in the development 
of more sophisticated tools. 
  
 
Figure 13. a) Structure of TRIM24 PROTAC 81 and starting point 80; b) 
Structure of BAZ2A/BAZ2B fragments 82 and 83; c) Crystal structures (PDB: 
5MGJ and 5MGK) of 82 (grey) and 83 (grey) bound to human bromodomain 
BAZ2A (green). 
BAZ2A/BAZ2B 
Bromodomain Adjacent to Zinc finger domain 2A/B (BAZ2A/B) 
are essential components of the chromatin remodelling complex 
NoRC (Nucleolar remodelling complex) and are implicated in the 
cell growth and disease recurrence of prostate cancer.99  
 At the time of our previous review, the BAZ2A/BAZ2B 
landscape contained multiple diverse BAZ2A/BAZ2B inhibitors. 
Since then, additional fragment inhibitors have been developed 
which offer promise for further BAZ2A/BAZ2B chemical probe 
development and diversification. 
Spiliotopoulos and co-workers have recently reported the 
discovery of two ligand efficient (LE >0.4) BAZ2A/BAZ2B 
inhibitors 82 and 83.100 In silico docking of 1413 small molecules 
into the acetylated lysine binding site of BAZ2A was used to 
identify an initial 20 small molecule fragment library which were 
then validated by ligand based NMR spectroscopy. 7 of the initial 
20 small molecules showed specific interactions with BAZ2A, 
which were then, in turn, evaluated in an in vitro competitive 
binding assay based on DNA-tagged BAZ2A bromodomain and 
polymerase chain reaction (PCR) quantification. X-ray 
crystallography was then used to compare the binding modes for 
82 and 83. As predicted by in silico docking, the aromatic rings of 
both 82 and 83 were shown to be sandwiched between the 
hydrophobic sidechains of the gate keeper residue (Val1879) and 
two other Val residues (Val1822 and Val1827), whilst the methyl 
lactam of 82 and the ethyl ketone of 83 were shown to act as the 
acetylated lysine mimetics (Figure 13c). Additionally, van der 
Waals interactions were observed between the 4-chloro and 3-
c) 
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ethyl-ester substituents of 82 and the side chains of Val1827 and 
Trp1816-Pro1817 respectively, whilst a weak polar interaction 
between the aromatic CH at position 2 and the carbonyl of 
Pro1817 was also observed. Optimization to install the required 
selectivity and physicochemical properties has been proposed 
through two growth pathways: 1) towards Glu1820/Leu1891 and 
2) towards Ser1828/Pro1899. 
 Although 82 (BAZ2A/BAZ2B pKD = 4.3/4.1) and 83 
(BAZ2A/BAZ2B pKD = 4.0/4.3) are not potent enough to be 
considered BAZ2A/BAZ2B inhibitors or chemical probes, they do 
offer two novel ligand efficient chemotypes for the development of 
future BAZ2A/BAZ2B chemical probes to add to the existing 
BAZ2A/BAZ2B chemical probe tool box.  
TAF1/TAF1L 
TAF1 and TAF1L are associated factors of the TATA binding 
protein (TBP), a large subunit of transcription factor II D (TFIID) 
and are believed to help facilitate the binding of TBP to DNA 
promoter regions and to add promoter selectivity. Like many 
BCPs, TAF1/TAF1L are believed to be associated with a number 
of oncology diseases, including cervical cancer,101 prostate 
cancer,102 and colorectal and gastric cancers103. Additionally, 
TAF1/TAF1L have been strongly linked to neurodegenerative 
diseases such as intellectual disability104 and X-linked dystonia 
parkinsonism.105 TAF1 and TAF1L both possess tandem 
bromodomains, with high homology shown across both 
bromodomains and the proteins in general (95% amino acid 
sequence). As a result, it is likely that compounds that bind TAF1 
will also bind TAF1L. Consequently, data is typically reported for 
TAF1(2) with almost no data reported for TAF1(1), TAF1L(1) or 
TAF1L(2). 
 Only one TAF1/TAF1L inhibitor (TAF1(2) pKD = 6.3), which 
showed a higher potency for the BET bromodomains, was 
disclosed at the time of our last review. Since then, the 
TAF1/TAF1L chemical tool repertoire has advanced dramatically 
in number, with multiple inhibitors being developed with improved 
potency (pKD > 7.0) and BET selectivity. Unfortunately, selectivity 
over other non-BET bromodomains has proven tricky, with 
several of the reported inhibitors displaying potency for other 
bromodomains.  
Whilst investigating BRD4 inhibition Sdelci and co-workers 
discovered a selection of small molecules that mimic BRD4 
inhibition, without binding to the target. One of these small 
molecules, CeMMEC13 (84), was shown to inhibit TAF1(2) (pIC50 
= 5.7) with selectivity against the BET subfamily (<20% inhibition 
against BRD4 at 10 µM). 84 also displayed selectivity over other 
non-BET bromodomains tested (<60% inhibition against BRD9, 
CREBBP and EP300 at 10 µM). In addition, 84 was also shown 
to engage TAF1(2) within REDS3 cells, confirming its cellular 
activity. CeMMEC15 (85) was also developed as a negative 
control, although the two compounds are structurally quite 
different. In addition compound 84 would benefit from further 
selectivity  
 
Figure 14. a) Structure of TAF1/TAF1L inhibitor 84 and accompanying negative 
control 85, and reference patent compound 86; b) Structures of reference patent 
TAF1(2) selective inhibitor 87 and panTAF1 inhibitor 88; c) Structures of TAF1 
inhibitor 90, intermediate 89 and starting compound 58; d) Structure of bivalent 
TAF1 inhibitors 91a-c;. 
characterization, in particular against the remaining non-BET 
bromodomains.106 Continuation of this research has lead the 
Research Center for Molecular Medicine to release a patent 
disclosing further TAF1 inhibitors.107 Although limited data is 
provided for the molecules, the most potent inhibitor (TAF1(2) 
pIC50 = 7.3) has been included for reference (86), and shows an 
increase in potency from 84. 
A series of TAF1 inhibitors have also been discovered by 
collaborative work between Genentech and Constellation 
pharmaceuticals and disclosed in a recent patent.108 208 
compounds were synthesized and tested for potency against both 
bromodomains of TAF1. Two compounds, the most selective 
TAF1(2) compound (87) and the most potent panTAF1 compound 
(88) have been included for reference. 87 displayed potency for 
TAF1(2) (pIC50 = 7.2) and was selective over TAF1(1) (pIC50 <4.7). 
By contrast, compound 88 displayed potency towards both 
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bromodomains of TAF1 (BD1/BD2 pIC50 = 7.1/7.7). It is currently 
unknown whether selective TAF1(2) inhibition or panTAF1 
inhibition is preferred, however, having access to inhibitors of 
each type will help elucidate this information. As to be expected 
for compounds disclosed in a patent, no information on selectivity, 
solubility, permeability or cellular target engagement has been 
disclosed. 
As discussed in the BRD7/9 section, Genentech and 
Constellation pharmaceuticals have reported selective 
bromodomain inhibitors where selectivity can be attributed to 
bromodomain specific interactions with the conserved water 
network found within the bromodomain binding pocket.78 
Substitution of the N-methyl group of hit molecule 58 for a 1-
butene group (89) dramatically reduced the potency for BRD4, 
BRD9, BRPF1, CREBBP and CECR2, whilst maintaining 
submicromolar potency for TAF1(2) (pIC50 =7.3). 89 was 
subjected to iterative structure-based drug design leading to 
90.109 Introduction of a morpholine group to the benzamide 
provided an optimal occupancy of the lipophilic-shelf region and 
an accompanying boost in TAF1(2) potency. Additionally, 
substitution off the phenyl ring was utilized to induce disfavourable 
protein surface interactions within BRD4(1), thus reducing 
BRD4(1) potency and improving BET selectivity. 90 displayed 
potency for TAF1(2) via TR-FRET (pIC50 = 8.0) and BROMOscan 
(pIC50 = 9.0) assays, and selectivity over the BET family (×2000). 
Furthermore, 90 was screened against 37 additional 
bromodomains via the BROMOscan panel where ≥1000-fold  
selectivity was observed excluding TAF1L(2) where equipotency 
was observed. Similarly, 90 appeared selective against a 35-
kinase panel (<17% inhibition observed at 1 µM). Finally, cellular 
target engagement was demonstrated using a NanoBRET assay 
where submicromolar potency (pIC50 = 7.4) was observed.  
 Exploiting the tandem nature of the bromodomains in TAF1, 
Frye and co-workers have reported the first examples of bivalent 
TAF1 inhibitors.110 Starting from the bromosporine derived ligand 
UNC4993, three bivalent TAF1 inhibitors were developed, each 
containing two UNC4993 monomers connected via polyethylene 
glycol (PEG) linkers. The most potent bivalent inhibitor, 91c, was 
shown to have a marginally enhanced potency (TAF1 pKD = 7.1) 
compared to the monovalent inhibitor (TAF1 pKD = 6.7), possibly 
attributable to the bivalent nature of the inhibitor. The 
bromodomain promiscuity of bromosporine ligands raises doubt 
over the selectivity of the inhibitors, in particular over the dual 
bromodomain BET subfamily, although theoretically this could be 
controlled by the linker length. Unfortunately, no selectivity data 
for the inhibitors is reported, nor for the monovalent inhibitor 
UNC4993. Additionally, no permeability or solubility data is 
provided, or evidence of target engagement. Absence of the  
above data highlights the caveats to using these bivalent 
inhibitors in target validation, however, further characterization 
could provide access to target validation of both TAF1 
bromodomains.  
Finally, as discussed previously, collaborative work 
between Bayer and the SGC has led to the identification of 47, a 
potent and selective inhibitor for both BRPF1 (pIC50 = 8.2) and 
TAF1(2) (pIC50 = 7.9). For the same reasons discussed previously, 
caution should be taken when using 47 as a sole TAF1/TAF1L 
chemical probe. 
Despite the growing number of diverse TAF1/TAF1L 
inhibitors, a lack of characterization, in particular regarding 
selectivity, suggests further TAF1/TAF1L inhibitor development is 
required to achieve adequate TAF1/TAF1L target validation. 90 
does, however, show major progress towards reaching this goal. 
Additionally, dissecting the individual roles of TAF1/TAF1L’s four 
bromodomains will also require further development into the 
possibility of non-pan TAF1/TAF1L inhibitors. 
SMARCA2/4 & PB1 
SMARCA2/4 and PB1 together make up the whole of sub family 
VIII and are all components of the mammalian SWI/SNF 
chromatin remodelling complex, where loss of function has been 
linked to several cancers.111,112 
 At the time of our previous review, the SMARCA2/4 
bromodomains had undergone minor target (in)validation using 
the single SMARCA2/4/PB1 inhibitor available. Since then, 
additional SMARCA2/4/PB1 inhibitors have been developed with 
improved characterization, including inroads into selectivity within 
the subfamily.  
Sutherell and co-workers have developed a collection of 
potent and selective SMARCA2/4/PB1 bromodomain inhibitors. 
Starting from a weakly potent, and poorly soluble, 
dihydropyrroloquinazolinone hit compound 92, structure guided 
optimization led to lead compound 93.113 X-ray crystallography 
was used to identify the two key hydrogen bond interactions 
between the carbonyl group and nitrogen atom of the 4-
quinazolinone scaffold, and the conserved Asn (Asn739) and Tyr 
(Tyr696). Similarly to previously reported SMARCA2/4/PB1(5) 
inhibitor PFI-3, 93 showed complete displacement of the 
conserved water molecules found within the binding pocket of 
SMARCA4. This distinctive binding action contrasts reported 
inhibitors of other bromodomains where the water molecules 
remain in place. A halogen bond between the chlorine atom and 
the carbonyl of a methionine residue (Met731) was also observed 
via X-ray crystallography (Figure 15c). Substitution of the chlorine 
for a bromine, in an attempt to create a stronger halogen bond, 
was countered by the steric constraint of the cavity. 93 
demonstrated potency for PB1 (pKD = 6.9), SMARCA2B (pKD = 
6.6) and SMARCA4 (pKD = 6.4), and selectivity against a selection 
of other representative bromodomains (BRD4, PCAF, CREBBP, 
TRIM33B). A full selectivity profile against the remaining 
bromodomains was not provided, and similarly no data was 
provided on activity for pharmacologically relevant off-targets. 
Furthermore, no solubility or permeability data was reported for 
93, although “improved” physicochemical properties are reported, 
and cellular activity was demonstrated at 1 µM using a FRAP 
assay. Finally, no structurally related negative control was 
provided for 93.  
Also of note was the development of 94, a biased PB1(5) 
inhibitor (ΔTm = 10.2 ºC) with reduced SMARCA4 potency (ΔTm = 
2.9 ºC), as measured by DSF, the first inhibitor reported to do so. 
ITC was used to confirm potency for PB1(5) (pKD = 6.8) and 
selectivity over SMARCA4 (pKD = 5.7). It was hypothesized that 
the introduction of the ethyl groups occupied the ill-defined 
peptide-binding channel present in PB1(5), which is blocked in 
SMARCA4 by Ile543. Although no structure was obtained to 
confirm the blocking in SMARCA4, this does potentially present a 
new avenue to pursue in the development of selective PB1 
chemical probes. 
 Additionally, a patent released by Genentech and 
Constellation Pharmaceuticals disclosed several SMARCA2/4 
and PB1(5) inhibitors containing a pyridazine scaffold.114 
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SMARCA4 potency data was reported for each compound, the 
most potent of which 95, has been included as reference. Potency 
against SMARCA2 and PB1(5) was also provided for select 
compounds and the most potent pan SMARCA2/4/PB1(5) triple 
inhibitor 96 has also been included.  
Finally, a SMARCA2/4 small molecule inhibitor (98) has 
been developed by Luo and co-workers.115 Starting from a HTS 
of 20,000 structurally diverse compounds, initial hit compound 97 
was identified as a novel SMARCA2/4 inhibitor (pIC50 = 4.4). A 
subsequent 2D similarity based search revealed 98 as a more 
potent (pIC50 = 5.0) SMARCA2/4 inhibitor, and molecular docking 
was utilized to identify the key interactions between 98 and the 
SMARCA2 bromodomain. A similar binding mode to previously 
reported SMARCA2/4 inhibitor PFI-3 was identified along with the 
traditional hydrogen bond interaction between the amine and the 
conserved Asn (Asn1464). An additional hydrogen bond 
interaction between the pyridine nitrogen and a backbone Phe 
(Phe1409) residue was also observed (to which the boost in 
potency can be attributed) along with the expected water 
mediated hydrogen bond to the conserved Tyr (Tyr1421). Further 
insight into the selectivity of 98 would be beneficial, in particular 
over the BET subfamily, SMARCA4 and PB1, however 98 does 
offer a new chemotype start point for further optimization in the 
pursuit of SMARCA2/4 chemical probes. 
Even with the addition of the above inhibitors, the 
SMARCA2/4/PB1(5) chemical tool pool remains shallow, with 
additional chemical probes required for all 3 BCPs for adequate 
target validation. In particular, improved selectivity between the 
bromodomains would allow for dissection of their individual 
pharmacology.  
3. Atypical Non-BET Bromodomain Inhibitors 
As eluded to in Section 1, atypical bromodomains do not possess 
the characteristic conserved Asn found throughout most 
bromodomains. Instead the Asn is mutated for a Tyr, Thr or Asp. 
As a result, the interactions we typically try to mimic with 
bromodomain inhibitors are different. Additionally, this causes a 
dramatic change to the depth of the atypical bromodomain binding 
pockets and overall increases the complexity of designing atypical  
 
 
Figure 15. a) Structure of SMARCA2/4/PB1 inhibitors 92-94; b) Structures of 
reference patent SMARCA2/4/PB1 inhibitors 95 and 96; c) Structures of 
SMARCA inhibitor 98 and initial start point 97; d) Crystal structure (PDB: 5FH8) 
of 94 (grey) bound to human bromodomain PB1(5) (orange) and the displaced 
water network. 
bromodomain inhibitors. At the time of our first review there were 
no reported atypical bromodomain inhibitors. Similarly, since that 
review, little progress has been made to tackle this issue, with 
atypical bromodomain chemical probes remaining a challenge for 
the future. 
PHIP 
Pleckstrin homology domain interacting protein (PHIP) was 
originally identified through interactions with insulin receptor 
signalling proteins, yet has recently been reported as being 
involved in oncology.116 More specifically PHIP has been 
identified as a promoter of melanoma metastasis and as a 
potential therapeutic target for breast and lung cancer, 
emphasising the need for further PHIP target validation.117,118 The 
second bromodomain of PHIP is atypical, with a Thr present 
within the binding site instead of the typical Asn which has made 
d) 
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the development of PHIP(2) inhibitors more challenging. Recently, 
however, compounds 99-101 have emerged as fragment hits 
from a study utilizing X-ray crystallography for fragment based 
drug discovery (Figure 16a).119 99 (PHIP(2) pIC50 = 3.9), 100 
(PHIP(2) pIC50 = 3.7) and 101 (PHIP(2) pIC50 = 3.6) together 
provide three diverse ligand efficient (>0.3) fragments for further 
optimization in the development of effective PHIP chemical 
probes, whilst critically demonstrating the potential for atypical 
bromodomain inhibition.  
SP100C 
The bromodomain of SP100C contains a Tyr in place of the 
commonly found Asn and has consequently been more 
challenging to inhibit effectively. As a result, the targeting of 
domain-domain interfaces has been proposed instead. Brennan 
and co-workers have reported two fragment inhibitors (102 & 103) 
of a novel binding site at the plant homeodomain-bromodomain 
interface. Soaking of SP100C crystals with 412 fragment 
compounds at 30 mM revealed 102 and 103 as fragment 
inhibitors of the novel binding site. X-ray crystallography 
confirmed the binding of the fragments to the identified binding 
site with no binding to SP100C’s bromodomain observed. 
Although no binding affinities were reported for the two fragments, 
they do provide insight into a novel approach for atypical 
bromodomain containing protein target validation, and potential 
start points for further optimization. 
4. Summary & Outlook 
Since our last review,13 the chemical probe research field has 
become dramatically more advanced and more precisely defined. 
As a result, the non-BET bromodomain chemical tool portfolio has 
flourished, with more potent, selective and in vivo capable tool 
molecules being developed. Currently 21/48 typical bromodomain 
containing proteins have at least 1 bromodomain inhibitor for 
target validation, with 19/48 possessing ≥3.  
The SAR accumulated through the development of 
bromodomain inhibitors has led to a greater understanding of 
each individual bromodomain and their key interactions, 
correlating to an increase in potency of the inhibitors developed 
over the past 3 and a half years. This is epitomized by CREBBP, 
for which inhibitors are now being developed with a log unit 
increase in affinity. Contradictorily, this detailed understanding of 
bromodomain binding pockets has also led to an increase in the 
successful development of inactive structurally similar negative 
controls, crucial in the assigning of phenotypical responses to 
target inhibition.  
Also vital to phenotype assignment is selectivity, which 
similarly has advanced dramatically since our last review. This is 
particularly evident with selectivity over the BET bromodomain 
subfamily, especially important due to the strong phenotype 
associated with the subfamily. Improved selectivity across the  
 
Figure 16. Structures of PHIP fragment hits 99-101 and SM100C fragment 
inhibitors 102 and 103. 
bromodomain family has allowed for more thorough and accurate 
target validation and will hopefully be maintained for future probe 
development.  
With a culmination of high quality non-BET bromodomain 
chemical probes, attention has even turned to the possibility of 
more sophisticated bifunctional tool molecules for target 
validation. Of particular note has been the development of non-
BET PROTACs and their potential for new pharmacology, not 
possible with bromodomain inhibitors alone. 
Despite the growing advances in typical bromodomain 
inhibition and target validation, the repertoire of atypical 
bromodomain chemical probes is still in its infancy, with only 2/13 
atypical bromodomain containing proteins having any form of 
reported inhibitor. Consequently, there remains a demand for a 
greater quantity of atypical bromodomain chemical probes which 
are also of higher quality. Hopefully moving forward this will be 
addressed as we begin to unravel the subtleties of atypical 
bromodomain inhibition. Additionally, advances into more 
sophisticated tool molecules for each bromodomain, along with 
continued effort to improve and diversify the inhibitors we develop, 
will help elucidate the biological tractability of bromodomain 
containing proteins. With luck this will facilitate sufficient target 
validation to reduce clinical attrition, and ultimately lead to the 
development of new therapeutics. 
In conclusion, non-BET bromodomain chemical probe 
development remains an exciting and vibrant area of research, 
particularly at the interface of academia and industry. Although 
clear strides have been made, and we are beginning to see this 
reflected in our understanding of the roles non-BET 
bromodomains play in modulating disease states, there remains 
a number of questions unanswered and avenues for improvement 
that are sure to be filled in the coming years. 
Keywords: non-BET bromodomains • chemical probe • target 
validation • epigenetics • acetylated lysine 
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